# Chemomab Therapeutics (CMMB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CMMB
## Company Profile
- Ticker: CMMB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel
- Tags: Immunology
## Stock Data
- Close: 1.39 USD
- Market cap: 12528657.72 USD
- Last updated: 2026-10-08
## Business Overview
### Immune-Fibrotic Disease Company
Chemomab Therapeutics is a clinical-stage biotechnology company developing therapies for diseases driven by fibrosis and inflammation. Its research is centered on CCL24, a soluble signaling protein implicated in immune-cell recruitment, tissue remodeling, and fibrotic disease progression.
### CCL24 Biology
CCL24 is believed to promote both inflammatory and fibrotic pathways, giving Chemomab a single target through which to address two interconnected components of immune-fibrotic disease. The company has built its therapeutic strategy around neutralizing CCL24 to alter the underlying biology rather than treating symptoms alone.
### Nebokitug
Nebokitug is a first-in-class monoclonal antibody designed to bind and neutralize CCL24. The candidate has demonstrated a generally favorable safety and tolerability profile across clinical studies and is intended as a platform therapy for multiple severe immune-mediated and fibrotic conditions.
### Primary Sclerosing Cholangitis Program
Chemomab evaluated nebokitug in the Phase 2 SPRING trial in primary sclerosing cholangitis, a chronic liver disease with no FDA-approved therapy. Biomarker analyses showed dose-dependent effects on inflammatory, immune, and tissue-remodeling signatures, including pathways relevant to patients with coexisting inflammatory bowel disease.
### Precision-Medicine Expansion into Rheumatoid Arthritis
Scipher Medicine's SPECTRA AI-enabled network-medicine platform identified nebokitug as a highly ranked clinical candidate for rheumatoid arthritis. Chemomab and Scipher plan to combine nebokitug with a molecular treatment-response signature designed to enrich a Phase 2 study for patients more likely to benefit from CCL24 inhibition.
## Why The Stock Is Moving

As of Oct 8, 2026, CMMB closed up 1.46% at $1.39. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of a Phase 2 precision-medicine trial of nebokitug in rheumatoid arthritis in the first half of 2027.
- Topline results from the Phase 2 nebokitug rheumatoid arthritis trial in the first half of 2028.

## Recent News
- 2026-08-31 12:00 EST — [Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-to-present-at-h-c-wainwright-28th-annual-global-investor-c-962fd6b3) — Source: Chemomab Therapeutics
- 2026-08-19 12:26 EST — [Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-second-quarter-2026-financial-results-and-provid-48b090e0) — Source: Chemomab Therapeutics
- 2026-07-08 11:30 EST — [Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-and-precision-medicine-pioneer-scipher-medicine-announce-m-14c02ebe) — Source: Chemomab Therapeutics
- 2026-05-14 12:00 EST — [Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Chemomab Therapeutics
- 2026-03-19 12:00 EST — [Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2025-financial-results-and-provides-a-corporate-update) — Source: Chemomab Therapeutics